Revenue growth is driven by Elfabrio sales through Chiesi, but the $25M milestone in Q1 2026 inflates year-to-date comparisons. Watch for Q4 2026 revenue to confirm whether the full-year guidance midpoint of $80.5M is achievable without additional milestones. PRX-115 Phase 2 data in H2 2027 is the next major catalyst.
Drugs in focus
PLX drug pipeline →PRX-115
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- If Phase 2 data in H2 2027 is positive, a Phase 3 program would follow, meaning potential FDA approval/commercialization is likely several years away, likely 2029-2031 at the earliest.
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 2 RELEASE study (NCT07280156) topline results, expected in the second half of 2027. Positive data showing sustained uric acid reduction with infrequent dosing could significantly de-risk the program and support a path to registration. Negative or equivocal results would likely weigh heavily on the stock given PRX-115's importance as the lead pipeline asset. Interim data or updates at medical conferences in the interim could also move the stock.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $2.86entry
- T+1 · 6d ago +9.44%α +8.12% · $3.13
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Protalix reported Q3 2026 total revenue of $21.9M, up 22.8% YoY from $17.9M, and net income of $4.0M ($0.05 per share) versus $2.4M a year ago. The company reaffirmed its full-year 2026 revenue guidance of $78M-$83M and expects to meet or exceed it. Cash grew to $48.5M, and the PRX-115 Phase 2 trial remains on track for top-line results in H2 2027.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue was $21.9M, up from $17.9M in Q3 2025
- Q3 2026 net income was $4.0M ($0.05 per share), up from $2.4M ($0.03 per share) in Q3 2025
- Nine-month 2026 total revenue was $75.6M, up from $43.6M in the same period of 2025
- Nine-month 2026 net income was $26.1M ($0.33 basic, $0.31 diluted), versus a net loss of $1.1M in the prior-year period
- Cash, cash equivalents, and short-term bank deposits were $48.5M at September 30, 2026
- Full-year 2026 revenue guidance reaffirmed at $78M-$83M, including a $25M milestone from Chiesi
- PRX-115 Phase 2 RELEASE study enrollment continues; top-line results expected in H2 2027
- Elfabrio received marketing authorization in Brazil for both every-two-weeks and every-four-weeks dosing
- Company has no outstanding debt or warrants
Financial Impact
Q3 2026 total revenue $21.9M, net income $4.0M, cash $48.5M
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Revenues from selling goods | $21.8M | +23.5% |
| Revenues from license and R&D services | $91.0K | -48.9% |
Risk Factors
- Revenue growth depends on continued Elfabrio penetration; any slowdown in Chiesi orders would impact results
- PRX-115 is still in Phase 2; clinical failure or delay would remove a key pipeline value driver
- Pfizer purchases have declined, partially offsetting Chiesi growth
- R&D expenses are rising as the RELEASE study progresses, pressuring margins
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-124761 |
| Document: plx-20261110x8k.htm | 0001104659-26-124761 |
| Document: 0001104659-26-124761-index-headers.html | 0001104659-26-124761 |
| Document: 0001104659-26-124761-index.html | 0001104659-26-124761 |
| Document: 0001104659-26-124761.txt | 0001104659-26-124761 |
| 8-K Data (Synthetic) | 0001104659-26-124761 |
Track record
3 reports on PLX
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Viewing Entry $2.86 Now $3.03 +5.94% settles Dec 9
- Oct 15, 20264w ago SC 13G Neutral 3/10 Entry $2.70 to $2.96 Now $3.03 +12.22% ▲ +9.63% +11.53% vs SPY
- Aug 12, 202613w ago 8-K Neutral 5/10 Entry $2.62 to $2.73 Now $3.03 +15.65% ▲ +4.20% +6.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers